Pharmaceutisch Weekblad

, Volume 9, Supplement 1, pp S87–S89 | Cite as

The use of fluoroquinolones in chronic otitis suppurativa

  • P. H. van de Heyning
  • S. R. Pattyn
  • H. D. Valcke
  • D. L. van Caekenberghe
  • J. Claes


The present review covers fluoroquinolone usage in chronic otitis suppurativa (COS) in case of chronic otitis media, cholesteatoma, radical mastoid cavity infection and chronic or relapsing otitis externa. A total of six publications were included in the final evaluation. Enoxacin was effective in 35%; ciprofloxacin (five publications) was used in 82 patients with 67% effectivity in otitis externa and otitis media and 61% effectivity in radical mastoid cavity infection. No serious adverse reactions were reported. The promising efficacy of otitis media and otitis extern and safety profile needs further confirmation in double blind prospective clinical studies, that will provide a firm basis for changing the current treatment schedules of COS.

Key words

Ciprofloxacin Enoxacin Mastoiditis Otitis media 


  1. 1.
    Paparella MM. The pathology of middle ear inflammation. Acta ORL Belg 1985;39:155–60.Google Scholar
  2. 2.
    Marquet JF, aVan de Heyning PH. Cholesteatoma or Keratoma, a pathological approach. Belg Tijdschr Radiol 1980;63:251–8.Google Scholar
  3. 3.
    Van de Heyning PH, Pattyn SR, Valcke HD. Ciprofloxacin in oral treatment of ear infections. Pharm Weekbl [Sci] 1986;8:63–6.Google Scholar
  4. 4.
    Alcock SR. Acute otitis extema in divers working in the North Sea: a microbiological survey of seven divers. J Hyg Camb 1977;78:395–407.PubMedGoogle Scholar
  5. 5.
    Papastravos T, Giamarellou H, Varlejides S. Role of aerobic and anaerobic micro-organisms in chronic suppurative otitis media. Larynscope 1986;96:438–42.Google Scholar
  6. 6.
    Brook I. Otitis media in children: a prospective study of aerobic and anaerobic bacteriology. Larynscope 1979;89:992–7.Google Scholar
  7. 7.
    Bluestone CD. Otitis media in children: to treat or not to treat? N Engl J Med 1982;306:1399–1404.PubMedGoogle Scholar
  8. 8.
    Fairbanks DN. Topical therapeutics for otitis media; Otolaryngol Head Neck Surg 1981;89:381–5.PubMedGoogle Scholar
  9. 9.
    Harada T, Iwamori M, Wagai Y, Nomura Y. Ototoxicity of neomycin and its penetration through the round window membrane into the perilymph. Ann. Otol Rhinol Laryngol 1986;95:404–8.PubMedGoogle Scholar
  10. 10.
    Lerner AM, Reyes MP, Copela, Blair DC, Jamen W, Wright GE, Lorber RR. Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1983;1:1123–6.PubMedGoogle Scholar
  11. 11.
    Chin NX, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1984;25:319–26.PubMedGoogle Scholar
  12. 12.
    Van Caekenberghe DL, Pattijn SR.In vitro activity of ciprofloxacin compared with those of other fluorinated piperazinylsubstituted quinolone derivates. Antimicrob Agents Chemother 1984;25:518–21.PubMedGoogle Scholar
  13. 13.
    Ball P. Ciprofloxacin: an overview of adverse experiences. J Antimicrob Chemother 1986;18:187–93.PubMedGoogle Scholar
  14. 14.
    Krajewski MJ. The effectiveness of enoxacin in the treatment of chronic suppurative otitis media. International Symposium on New Quinolones, Geneva, 1986, July 17–19.Google Scholar
  15. 15.
    Höffken G, Lode HK, Prinzig C. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother, 1985;27:375–9.PubMedGoogle Scholar
  16. 16.
    Ullmann U, Giebel W, Dachhoff A, Koeppe P. Single and multiple dose pharmaco-kinetics of ciprofloxacin. Eur J Clin Microbiol 1986;5:193–6.PubMedGoogle Scholar
  17. 17.
    Giamarellou H, Galanakis N, Dendrinos C, Stefanou J, Daphnis E, Daikos GK. Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol 1986;5:232–5.PubMedGoogle Scholar
  18. 18.
    Ganz H. Gyrasehemmer in der Lokalbehandlung von mit Problemkeimen chronish infizierten Mittelollroperationshöhlen. HNO 1986;24:511–4.Google Scholar
  19. 19.
    Fedelspil P. Efficacy and safety of ciprofloxacin in ear, nose and throat infections. In Proceedings First Internat. Ciprofloxacin Workshop, Leverkusen, Excerpta Media, 1986: 399–401.Google Scholar
  20. 20.
    Van de Heyning PH, Valcke HD, Pattyn SR, Van Caeckenberghe DL, Jans DL, Chysky HW, Boerema JB. The use of ciprofloxacin in surgical and non surgical ear-note-throat infections. International Symposium on Quinolones. Geneva, 1986, July, 17–9.Google Scholar
  21. 21.
    Ganz H. Clinical efficacy of ciprofloxacin in Otorhinolaryngological infections. In Proceedings First International Ciprofloxacin Workshop, Leverkusen, 1986. Excerpta Medica, 1986;395–6.Google Scholar

Copyright information

© Bohn, Scheltema & Holkema 1987

Authors and Affiliations

  • P. H. van de Heyning
    • 1
  • S. R. Pattyn
    • 2
  • H. D. Valcke
    • 1
  • D. L. van Caekenberghe
    • 2
  • J. Claes
    • 1
  1. 1.Department of Otolaryngology and Head and Neck Surgery, University Hospital AntwerpUniversity of AntwerpAntwerpBelgium
  2. 2.Department of Medical Microbiology, University Hospital AntwerpUniversity of AntwerpAntwerpBelgium

Personalised recommendations